Key members of the research collaboration: (from left) Prof Roger Foo (Programme Director, ATTRaCT, and Senior Group Leader, GIS), Dr Karin Conde-Knape (Senior Vice President, Global Drug Discovery, Novo Nordisk), Dr Rasmus Rabøl (Corporate Vice President, Global Translation, Novo Nordisk), Dr Natasha Michaelsen (Principal Scientist, Global Translation, Novo Nordisk), Prof Mark Richards (Director, Cardiovascular Research Institute, NUS, and Deputy Director, National University Heart Centre), Prof Derek Haus
News | Heart Failure
A*STAR, NHCS, NUS, and Novo Nordisk to Collaborate on Cardiovascular Disease Research

May 16, 2022 — The Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS) and ...

Home May 16, 2022
Home
A substantial proportion of patients with COVID and shock had low CI despite preserved EF, suggesting underfilling of the LV, but this proportion was smaller in W2. This difference could not be explained by changes in PEEP between cohorts. This suggests that fluid management strategies may have been more aggressive in W2.
News | Coronavirus (COVID-19)
New Report Published Comparing Hemodynamics of Cardiac Shock in COVID-19 Patients in Pandemic’s First Vs. Second Wave

May 16, 2022 — A new report by a team of cardiologists from the Heart & Vascular Hospital, Hackensack Meridian ...

Home May 16, 2022
Home
Pump housing and impeller design. (A): (left) Axial flow pump: HeartMate II LVAD (taken from Figure 2 in the HeartMate II left ventricular assist system instructions for use). (B) (right) Centrifugal flow pump: HeartWare assist device (taken from Figure 2 in the HeartWare assist device patient manual).
News | Heart Failure
Study Finds that Concurrent Tricuspid Valve Surgery and Left Ventricular Assist Device Implantation do not Appear to Lower the Incidence of Right Heart Failure

May 16, 2022 — Right heart failure (RHF) continues to be a major source of morbidity and mortality following left ...

Home May 16, 2022
Home
CRF Meeting Covering Structural Heart Disease Innovations Will Take Place June 8-10
News | TVT
Late-Breaking Science Announced for TVT 2022

May 16, 2022 — The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature ...

Home May 16, 2022
Home
Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData
News | Pharmaceuticals
Bristol Myers Squibb’s Mavacamten Poised to Stand unchallenged

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...

Home May 13, 2022
Home
Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced successful completion of patient enrollment in the company’s AcQForce Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally
News
Acutus Medical Completes Enrollment in IDE Trial with its AcQBlate FORCE Sensing Ablation System

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
Woon-Hong Yeo has developed a smarter stent. Georgia Tech Photo
News | Stents
Georgia Tech Researchers Develop Wireless Implantable Vascular Monitoring System

May 13, 2022 — Vascular diseases are public enemy number one: the leading killers worldwide, accounting for nearly a ...

Home May 13, 2022
Home
The Neurescue device is an FDA-approved device currently in use for patients with severe bleeding which will now be used in a new study to help increase survival rate for those who experience in-hospital cardiac arrests
News | Sudden Cardiac Arrest
MemorialCare Long Beach Medical Center Only Site in Nation to Offer ARISE-Study – New Experimental Treatment for In-Hospital Cardiac Arrest

May 13, 2022 — The MemorialCare Heart & Vascular Institute at Long Beach Medical Center has been designated the only ...

Home May 13, 2022
Home
Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists
News | Cardiovascular Business
Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials

May 12, 2022 — Abbott announced a new partnership with Women as One to launch a new program designed to train more ...

Home May 12, 2022
Home
The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032, expanding at a CAGR of 6.2% over the 2022-2032 time frame.
Feature | Cardiogenic Shock
Cardiogenic Shock Market Outlook

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032 ...

Home May 12, 2022
Home
Integrated patch offers ECG, heart rate, respiratory rate, and blood pressure monitoring for commercial research and development
News | Remote Monitoring
Vivalink Announces World’s First Multi-Vital Blood Pressure Patch for Remote Patient Monitoring

May 12, 2022 — Vivalink, a leading provider of digital healthcare solutions, announced availability of the world’s first ...

Home May 12, 2022
Home
Peter Mackrell, MD
News | Cardiovascular Business
Board Certified Vascular Surgeon Joins NDA Partners as Expert Consultant

May 12, 2022 — NDA Partners General Manager, Eric Fish, announced today that Peter Mackrell, MD, a board certified ...

Home May 12, 2022
Home
NIH-funded study explains factors linked to increased risk for heart attack or stroke among women who have pregnancy problems related to high blood pressure
News | Womens Cardiovascular Health
Hypertensive Pregnancy Disorders Linked to Future Cardiac Events

May 11, 2022 — Women who experienced complications related to developing high blood pressure, or hypertension, during ...

Home May 11, 2022
Home
A microscopy picture of muscle cells in a normal heart (left) and muscle cells in a heart of a patient with hypertrophic cardiomyopathy (right). The black areas are single muscle cells. The muscle cells of the hypertrophic cardiomyopathy patient are bigger, and there is more space in between the cells (green), which is filled with scar tissues in the case of patients with hypertrophic cardiomyopathy. The blue indicates where the DNA of the cells can be found. Image courtesy of Anne de Leeuw, copyright Hubre
News | Cardiovascular Clinical Studies
Single Cell RNA Sequencing Uncovers New Mechanisms of Heart Disease

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
Gay Nord
News | Cardiovascular Business
Vital Heart & Vein Names Gay Nord, MHA as New CEO

May 11, 2022 — Vital Heart & Vein, a leading provider of cardiovascular and vein health, has named Gay Nord as its new ...

Home May 11, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now